BCL2 and triple-negative breast carcinoma: The combination of 3-MA and gefitinib (Ge) enhance the effect of treatment in triple-negative breast cancer in vitro and in vivo. An increased level of BAX/Bcl-2, cytochrome C and CASP3 has been observed